Support teaching, research, and patient care.
International
true
false
Hepatobiliary imagingHepatocellular carcinomaUrologic imagingGynecologic imagingThyroid imagingNovel ultrasound technologiesPerfusion CT imaging of abdominal tumors
Phase I Pilot Study to Evaluate the Prognostic Value of Perfusion CT for Primary Cervical Cancer Not Recruiting
The investigators hope to learn whether perfusion CT is a useful way to assess primary cervical tumor microenvironment and whether there is a relationship between pretreatment perfusion CT measurements and primary cervical tumor size, lymph node involvement (as assessed by standard of care pretreatment fludeoxyglucose Positron emission tomography/CT (FDG-PET/CT)), and treatment response (as assessed by standard of care 3-month post-therapy FDG-PET/CT).
Stanford is currently not accepting patients for this trial. For more information, please contact Melissa Usoz, 650-723-8843.
View full details
Developing Non-Invasive Early Therapeutic Monitoring to Predict Treatment Efficacy in RCC Not Recruiting
This pilot clinical trial studies perfusion computed tomography (CT) in predicting response to treatment in patients with advanced kidney cancer. Comparing results of diagnostic procedures done before, during, and after targeted therapy may help doctors predict a patient's response to treatment and help plan the best treatment.
Stanford is currently not accepting patients for this trial. For more information, please contact Yoriko Imae, 650-498-5186.
Elastography in Thyroid Nodule Evaluation Not Recruiting
This clinical trial studies how well ultrasound elastography works in assessing the cancer status of potentially malignant thyroid nodules.
Stanford is currently not accepting patients for this trial. For more information, please contact Harris Naemi, 650-736-6524.
Perfusion CT as a Predictor of Treatment Response in Patients with Rectal Cancer Not Recruiting
A research study of rectal cancer perfusion (how blood flows to the rectum over time). We hope to learn whether perfusion characteristics of rectal masses may be predictive of response to treatment and whether rectal perfusion characteristics can be used to follow response to treatment.
Stanford is currently not accepting patients for this trial. For more information, please contact Laura Gable, 650-736-0798.
Phase TBD Development of 3D MPUS as Decision Support Tool for Patients abdominal and pelvic tumors Recruiting
This clinical trial studies how well 3-dimensional multi-parametric ultrasound (3D MPUS) imaging works as a decision-support tool for patients with liver tumors undergoing therapy. Continuous and dynamic imaging of patients undergoing therapy is required to monitor early-phase treatment response. 3D-MPUS is an inexpensive and safe method, which may provide complementary quantitative functional (perfusion) and tissue characterization information to anatomical radiological assessment or blood biomarkers.
Pilot 3D Contrast-Enhanced Ultrasound Imaging to Predict Treatment Response in Liver Metastases Not Recruiting
Patients are invited to participate in a research study of liver perfusion (how blood flows to the liver over time). Researchers hope to learn whether perfusion characteristics of liver metastases may be predictive of response to treatment and whether liver perfusion characteristics can be used to follow response to treatment. Patients were selected as a possible participant in this study because they are identified as having liver metastases
Stanford is currently not accepting patients for this trial. For more information, please contact Risa Jiron, 650-736-1598.
CE Ultrasound Eval of Focal Liver Lesions in Cirrhosis /Other Risk Factors for Developing HCC Not Recruiting
This clinical trial studies how well contrast-enhanced ultrasound imaging works in diagnosing liver cancer in patients with cirrhosis. Diagnostic procedures, such as contrast-enhanced ultrasound imaging, may help find and diagnose liver cancer.
Stanford is currently not accepting patients for this trial. For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
US Elastography for Characterizing Focal Lesions in the Liver & Kidney Not Recruiting
This clinical trial studies ultrasound elastography in diagnosing patients with kidney or liver solid focal lesions. New diagnostic procedures, such as ultrasound elastography, may be a less invasive way to check for kidney or liver solid focal lesions.
Stanford is currently not accepting patients for this trial. For more information, please contact Juergen Willmann, 650-725-1812.
Perfusion CT as a Predictor of Treatment Response in Patients with Hepatic Malignancies Not Recruiting
A research study of liver perfusion (how blood flows to the liver over time). We hope to learn whether perfusion characteristics of liver masses may be predictive of response to treatment and whether liver perfusion characteristics can be used to follow response to treatment.
Stanford is currently not accepting patients for this trial. For more information, please contact Elizabeth Chitouras, 650-498-0623.
Transabdominal Ultrasound with BR55 for Characterization of Pancreatic Lesions Not Recruiting
This is an exploratory, single center, open label, parallel-dose, and prospective study of BR55 contrast-enhanced ultrasonography (CEUS) for characterization of solid pancreatic lesions in subjects with suspected pancreatic ductal adenocarcinoma (PDAC) using transabdominal US.
Stanford is currently not accepting patients for this trial. For more information, please contact Krithika Rupnarayan, MPH, MBBS, 650-736-0959.
Pilot Quantitative Ultrasound Spectroscopy to Detect HCC Not Recruiting
This pilot trial studies how well B-mode ultrasound imaging works in detecting liver cancer that is early in its growth and may not have spread to other parts of the body. Diagnostic procedures, such as B-mode ultrasound imaging, may help find and diagnose liver cancer and find out how far the disease has spread.
Stanford is currently not accepting patients for this trial. For more information, please contact Sunitha Bachawal, 650-724-1472.
Prognostic Value of Baseline CT Perfusion Parameters of Pancreatic CA for SBRT or Surgical Resection Not Recruiting
The purpose of this study is first, to determine whether baseline perfusion characteristics of pancreatic cancer, as characterized by CT perfusion studies, can predict tumor response to treatment by stereotactic body radiotherapy (SBRT). The second goal of this study is to determine whether baseline perfusion characteristics in those patients with resectable pancreatic cancer correlate with immunohistologic markers of angiogenesis such as microvessel density and vascular endothelial growth factor (VEGF) expression.
Stanford is currently not accepting patients for this trial. For more information, please contact Lindee Burton, 6507254712.
